Skip to main content

PRESS RELEASES

Date Title  
Toggle Summary Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on March 8, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 2, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on March 8, 2018 at 8:00 a.m. ET to discuss fourth quarter 2017 results and provide a general business update.
Toggle Summary Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2018-- Seres Therapeutics, Inc. , (NASDAQ:MCRB) today announced the appointment of Eric D. Shaff to the additional role of Chief Operating Officer. Mr. Shaff has been Executive Vice President and Chief Financial Officer since joining the Company in
Toggle Summary Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 4, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that it will present at the 36 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11 at 8:30 a.m. PT . A live audio webcast of the presentation and breakout
Toggle Summary Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis
- Microbiome analyses demonstrate engraftment of SER-287-derived bacteria; microbiome compositional changes correlate with clinical remission - - SER-287 engraftment maintained four weeks after completion of dosing - - Company to discuss proposed SER-287 development plan with FDA and intends to
Toggle Summary Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 4, 2017-- Seres Therapeutics, Inc. , (NASDAQ:MCRB) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation to microbiome therapeutic candidate SER-287 for the treatment of Ulcerative Colitis (UC) in pediatric
Toggle Summary Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 14, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB), The University of Texas MD Anderson Cancer Center (MD Anderson), and the Parker Institute for Cancer Immunotherapy ( Parker Institute ) today announced a collaboration to evaluate the potential of Seres’
Toggle Summary Seres Therapeutics to Participate in Three Upcoming November Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2017-- Seres Therapeutics, Inc ., (NASDAQ:MCRB) today announced that it will participate in each of the following upcoming healthcare conferences: Stifel 2017 Healthcare Conference: A corporate overview will be presented on Tuesday, November 14 at 5:00
Toggle Summary Seres Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Operational Progress
– Positive results from SER-287 Phase 1b study in mild-to-moderate Ulcerative Colitis; Company to move program into further development – – Company awarded CARB-X grant to advance SER-155 for allogeneic stem cell and solid organ transplantation – – Conference call at 8:00 a.m.
Toggle Summary Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate
– SER-155, a preclinical stage, synthetic microbiome therapeutic candidate, is being developed to prevent serious bacterial infections and graft versus host disease in patients following solid organ and allogeneic stem cell transplantation – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov.
Toggle Summary Seres Therapeutics to Host Third Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2017-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on November 8, 2017 at 8:00 a.m. ET to discuss third quarter 2017 results and provide a general business update.

Back to top